Champions Oncology, Inc.CSBRNASDAQ
Loading
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue Growth | +41.77% | -11.76% | -0.47% | +11.46% | -2.82% |
| Gross Profit Growth | +140.38% | -30.53% | -13.73% | +30.98% | -26.34% |
| EBITDA Growth | +0.00% | -690.23% | -105.27% | -46.22% | -96.87% |
| Operating Income Growth | +0.00% | -1145.12% | -138.15% | -74.73% | -104.16% |
| Net Income Growth | +0.00% | +0.00% | -133.21% | -58.93% | -106.21% |
| EPS Growth | +0.00% | +0.00% | -132.71% | -63.81% | -106.06% |
| EPS Diluted Growth | +0.00% | +0.00% | -133.80% | -64.35% | -106.45% |
| Weighted Average Shares Growth | +0.79% | +1.18% | +1.43% | +1.46% | +1.36% |
| Weighted Average Shares Diluted Growth | +5.67% | +1.18% | -1.81% | +3.15% | -3.33% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +92.93% | +0.00% | -373.27% |
| Free Cash Flow Growth | +0.00% | +0.00% | +78.14% | +0.00% | -407.14% |
| Receivables Growth | +99.90% | +17.93% | +4.89% | +10.21% | -23.54% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +14.34% | +23.77% | +22.51% | +19.50% | -7.12% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +503.54% | -22.74% |
| Debt Growth | -16.86% | -17.83% | -19.09% | -22.23% | -22.34% |
| R&D Expense Growth | -21.36% | -4.20% | +43.19% | +54.88% | +32.11% |
| SG&A Expenses Growth | -16.55% | -2.14% | +8.25% | +53.41% | +48.21% |